<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611480</url>
  </required_header>
  <id_info>
    <org_study_id>LIMTOP-I</org_study_id>
    <nct_id>NCT01611480</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moberg Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moberg Pharma AB</source>
  <brief_summary>
    <textblock>
      The aim is to evaluate efficacy and safety of three different dosing regimens of Limtop in a
      study involving 96 patients with actinic keratosis on the head or face.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Actinic Keratosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod (topical use)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent form (ICF) signed and dated by the patient prior to any
             study-related activity

          2. Male or female patients aged 18 or older

          3. Have a total of 5-20 clinically confirmed, palpable or visible (grade I or II
             according to modified Olsen score) nonhyperkeratotic, nonhypertrophic AK lesions
             located within a contiguous 25 - 100 cm² area on the balding scalp or face

          4. Any skin type or race, providing the skin pigmentation will allow discernment of
             erythema

          5. Willingness to actively participate in the study and to comply with the study
             procedures as defined in the study protocol

          6. High probability of a good compliance and orderly completion of the study

          7. Negative urine pregnancy test (in female subjects with childbearing potential)

        Exclusion Criteria:

          1. Evidence of clinically significant, unstable cardiovascular or immunosuppressive,
             hematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or
             gastrointestinal abnormalities or disease

          2. Diagnosed autoimmune diseases and anaemia

          3. Any dermatological disease and or condition in the treatment or surrounding area that
             may be exacerbated by treatment with imiquimod or cause difficulty with examination
             (e.g. rosacea, psoriasis, atopic dermatitis, eczema)

          4. Any significant findings (e.g. tattoos) in the potential application site area that
             may impair examination of treatment or surrounding area

          5. Confirmed squamous cell or basal cell carcinoma anywhere on the head in the past 3
             months

          6. Share a household where there is a person participating in a concurrent clinical study
             of imiquimod or being treated with imiquimod 5% topical cream

          7. Active chemical dependency or alcoholism, as assessed by investigator

          8. Patients unwilling to stay out of the sun or wear protective clothing or to take
             appropriate measures to cover the treatment area during the study

          9. Previous treatments with imiquimod for AK in the predetermined treatment area within
             the past 3 months

         10. Treatment with COX-2 inhibitors 14 days prior to randomization

         11. Currently using or have used on the treatment area over-the-counter retinol products,
             corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic
             keratosis treatments 28 days prior to randomization

         12. Subjects who experienced an unsuccessful outcome from previous imiquimod therapy.

         13. Known allergy or sensitivity to imiquimod or any of the excipients (butyl lactate,
             isopropyl myristate, propylene glycol, butylated hydroxy anisole) in the IMP

         14. Pre-menopausal (last menstruation ≤ 1 year prior to screening) sexually active women
             who:

               -  are pregnant or nursing,

               -  are not surgically sterile,

               -  are of child bearing potential and not practicing an acceptable method of birth
                  control, or does not plan to continue practicing an acceptable method of birth
                  control throughout the trial (acceptable methods include intrauterine devices
                  (IUD), oral, implantable or injectable contraceptives, diaphragm or cervical cap
                  with intravaginal spermicide, condom with intravaginal spermicide or vasectomised
                  partner)

         15. Participation in another clinical trial with an investigational drug or device during
             the previous 4 weeks before Baseline

         16. Receiving systemic cancer chemotherapy, psoralen plus UVA therapy, UVB therapy, laser
             abrasion, dermabrasion, glycolic acids, or chemical peels 6 months prior to study
             entry.

         17. Currently using or have used systemic steroids 2 months prior to study except inhaled
             corticosteroids (&lt;1200 microgram/day for beclomethasone, or &lt;600 microgram/day for
             fluticasone)

         18. Known infectious diseases (e.g. HIV, hepatitis)

         19. Psychiatric condition that might limit the participation in the study and/or that lead
             to the assumption that the ability to completely understand the consequences of
             consent is missing

         20. The Patient is institutionalized by virtue of an order issued either by the judicial
             or the administrative authorities

         21. Employee of the study site or of the Sponsor's company

         22. Any disease or circumstances on account of which the subject should not participate in
             the study in the opinion of the investigator -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>5 Locations</name>
      <address>
        <city>Germany</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

